Antinuclear Antibodies and Lupus-like Manifestations in Rheumatoid Arthritis and Ankylosing Spondylitis Patients at 4 Months' Follow-up After Treatment with Infliximab and Etanercept
Up to 44% of patients treated with infliximab and 7% of patients treated with etanercept reported having anti-drug antibodies within the first 6 months of treatment. Recently, anti-TNF-α therapies have been reported in induction of the drug-induced lupus erythematous. The aim of present study was to investigate relationship between anti-TNFα antibodies and various manifestations of lupus erythematous. We enrolled a total 56 cases divided into 28 known cases of rheumatoid arthritis and 28 cases of ankylosing spondylitis patients and 56 controls. Case group was divided into 4 groups according to underlying disease (RA or AS) and treatment regimen (infliximab or etanercept). ANA and anti-dsDNA levels and lupus criteria were assessed at the beginning of study and 4 months after initiation of anti-TNFα. 36% and 21% of RA patients treated with infliximab, were ANA and anti-dsDNA positive after 4 months (P=0.003, P=0.025). 28% and 7% of RA patients treated with etanercept, were ANA and anti-dsDNA positive after 4 months (P=0.009, P=0.15). 21% and 7% of AS patients treated with infliximab, were ANA and anti-dsDNA positive, respectively (P=0.025, P=0.15). 14% and 7% of AS patients treated with etanercept, were ANA and anti-dsDNA positive, respectively (P=0.63, P=0.15). Our study showed that infliximab potentially may increase both ANA and anti-dsDNA levels in rheumatoid arthritis, but only ANA in ankylosing spondylitis patients. Etanercept led to positive ANA in rheumatoid arthritis patients, although neither ANA and anti-dsDNA became positive in ankylosing spondylitis patients treated with etanercept.